Fecal calprotectin as a promising marker of inflammatory diseases

Bratislava Medical Journal

Volumn 110, Issue 10, 2009, Pages 598-602

  Paduchova, Z ^a   Durackova, Z ^a  

^a Physics and Informatics   (Slovakia)

Author keywords

Calprotectin; Crohn's disease; Inflammatory bowel disease (IBD)

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN;

ADOLESCENT; ARTICLE; CHEMISTRY; CHILD; ENTERITIS; FECES; FEMALE; HUMAN; MALE; METABOLISM;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE;

EID: 75649086982     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Angriman I, Scarpa M, D,Inca R et al. Enzymes in feces: Useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007; 381:63-68.
2. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1: 514.
3. Hyams JS, Ferry GD, Mandel FS et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12 (4): 439-447.
4. Hyams J, Markowitz J, Otley A et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005; 41 (4): 416-421.
5. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-431.
6. Konikoff MR, Denson LA. Role of calprotectin as a biomarker of intestinal inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 524-534.
7. Fagerhol MK, Dale I, Andersson I. Release and quantitation of a leucocyte derived protein (LI). Scan J Haematol 1980; 24: 393-398.
8. Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of highly immunogenic human leukocyte protein, the LI antigen. Eur J Biochem 1983; 134: 1-6.
9. Kligman D, Hilt DC. The S100 protein family. Trends Biochem Sci 1988; 13: 437-443.
10. Fagerhol MK, Andersson KB, Naess-Andresen CF et al. Calprotectin (The LI leukocyte protein). 187-210. In: Smith VL and Dedman JR (Eds). Stimulus response coupling: The role of intracellular calciumbinding proteins. CRC Press; Boca Raton, 1990.
11. Naess-Andressen CF, Egelandsdal B, Fagerhol MK. Calcium binding and concomitant changes in the structure and heat stability of calprotectin (LI protein). J Clin Patho Mol Pathol 1995; 316: M278-284.
12. 2+ -binding proteins of neutrophils and monocytes. J Leukoc Biol 1993; 53: 197-204.
13. Boussac M, Garin J. Calcium-dependent secretion in human neutrophils: aproteomic approach. Electrophoresis 2000; 21: 665-672.
14. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997; 272 (14): 9496-9502.
15. Voganatsi A, Panyutich A, Miyasaki KT, Murthy RK. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol 2001; 70: 130-134.
16. Brandtzaeg P, Dale I, Fagerhol MK. Distribution of a formalin-resistant myelomonocytic antigen (Li) in human tissues. I. Comparison with other leukocyte markers by paired immunofluorescence and immunoenzyme staining. AmER J Clin Pathol 1987; 87: 681-699.
17. Tibbie JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001; 7 (4): 460-465.
18. Tibbie JA, Bjarnason I. Fecal calprotectin as an index in intestinal inflammation. Drugs Today (Brae) 2001; 37 (2): 85-96.
19. Brun JG, Ulvestad E, Fagerhol MK, Jonsson R. Effect of human calprotectin (LI) on in vitro immunoglobulin synthesis. Scand J Immunol 1994; 40: 675-680.
20. Yui S, Mikami M, Tsurumaki K, Yamazaki M. Growth-inhibitory and apoptosis inducing activities of calprotectin derived from inflammatory exudate cells on normal fibroblasts: regulation by metal ions. J Leukoc Biol 1997; 61: 50-57.
21. Steinbakk M, Naess-Andersen C-F, Lingaas E et al. Antimicrobial actions of calcium binding leucocyte Liprotein, calprotectin. Lancet 1990; 336: 763-765.
22. Sohnle PG, Collins-Lech C, Wiessner JH. The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. J Infect Dis 1991; 164: 136-142.
23. Hahn BL, Sohnle PG. Resistance of zinc-supplemented Candida albicans cells to the qrowth inhibitory effect of calprotectin. J Infect Dis 1995; 171: 1289-1294.
24. Levy O. Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. Blood 2000; 96: 2664-2672.
25. Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. The Lancet 2000; 356: 1783-1784.
26. Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003; 18: 756-762.
27. Burkhardt K, Radespiel-Troger M, Rupprecht HD et al. An increase in myeloid-related protein serum levels precedes acute renal allograft rejection. J Amer Soc Nephrol 2001; 12: 1947-1657.
28. Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing LI protein (calprotectin) in human Peyer,s patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993; 34: 1357-1363.
29. Fagerhol MK. Nomenclature for proteins: is calprotectin a proper name for the elusive myelomonocytic protein? J Gastroenterol 1996; 49: 74-79.
30. Aadland E, Fagerhol MK. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 823-825.
31. Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002; 91: 45-50.
32. Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13 (2): 279-284.
33. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 176-180.
34. Tibbie JA, Sigthorsson G, Bridger S et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
35. Ton H, Brandsnes O, Dale S, Holtlund J, Skuibina E, Schjonsby H, Johne B. Improved assay for fecal calprotectin. Clin Chim Acta 2000; 292: 41-54.
36. Wagner M, Peterson CGB, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14 (36): 5584-5589.
37. D,Inca R, Del Pont E, DiLeo V et al. Can calprotectin predict relaps risk in inflammatory bowel disease? Amer J Gastroenterol 2008; 103 (8): 2007-2014.
38. Diamanti A, Colistro F, Basso MS et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis 2008; 14 (9): 1229-1235.